Corbus Pharmaceuticals (CRBP) Stock Forecast, Price Target & Predictions
CRBP Stock Forecast
Corbus Pharmaceuticals stock forecast is as follows: an average price target of $74.00 (represents a 32.59% upside from CRBP’s last price of $55.81) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
CRBP Price Target
The average price target for Corbus Pharmaceuticals (CRBP) is $74.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $88.00 to $46.00. This represents a potential 32.59% upside from CRBP's last price of $55.81.
CRBP Analyst Ratings
According to 5 Wall Street analysts, Corbus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRBP stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Corbus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | Graig Suvannavejh | Mizuho Securities | $74.00 | $51.58 | 43.47% | 32.59% |
| Aug 07, 2024 | Jeff Jones | Oppenheimer | $88.00 | $48.30 | 82.19% | 57.68% |
| Jul 22, 2024 | Andres Maldonado | H.C. Wainwright | $80.00 | $58.00 | 37.93% | 43.34% |
| Jun 11, 2024 | Brian Abrahams | RBC Capital | $82.00 | $43.87 | 86.92% | 46.93% |
| Jun 03, 2024 | Jeff Jones | Oppenheimer | $80.00 | $42.80 | 86.92% | 43.34% |
| May 20, 2024 | Brian Abrahams | RBC Capital | $77.00 | $45.00 | 71.11% | 37.97% |
| Mar 06, 2024 | Maury Raycroft | Jefferies | $46.00 | $33.58 | 36.99% | -17.58% |
The latest Corbus Pharmaceuticals stock forecast, released on Sep 13, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $74.00, which represents a 43.47% increase from the stock price at the time of the forecast ($51.58), and a 32.59% increase from CRBP last price ($55.81).
Corbus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 7 |
| Avg Price Target | $74.00 | $80.67 | $75.29 |
| Last Closing Price | $55.81 | $55.81 | $55.81 |
| Upside/Downside | 32.59% | 44.54% | 34.90% |
In the current month, the average price target of Corbus Pharmaceuticals stock is $74.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 32.59% increase as opposed to Corbus Pharmaceuticals's last price of $55.81. This month's average price target is down -8.27% compared to last quarter, and down -1.71% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 29, 2024 | Wedbush | - | Outperform | Initialise |
| Jun 25, 2024 | B. Riley | - | Buy | Initialise |
| Jun 11, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jun 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 20, 2024 | RBC Capital | Outperform | Outperform | Hold |
| May 13, 2024 | RBC Capital | - | Outperform | Initialise |
| Mar 06, 2024 | Jefferies | - | Buy | Upgrade |
| May 10, 2023 | Oppenheimer | - | Outperform | Upgrade |
Corbus Pharmaceuticals's last stock rating was published by Oppenheimer on Aug 07, 2024. The company gave CRBP a "Outperform" rating, the same as its previous rate.
Corbus Pharmaceuticals Financial Forecast
Corbus Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-233.88K | $97.32K | $136.56K | $647.82K | $658.20K | $1.23M | $286.35K | $1.76M | $2.57M | $2.59M | $29.09M | $1.89M | $1.09M | $853.65K |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $1.35M | $570.35K | $200.00K | $150.00K | $347.50K | $978.00K | $885.50K | $952.00K | $1.49M | $3.24M | $3.39M | $2.41M | $3.69M | $1.84M | $12.50M | $2.73M | $923.05K | $853.65K |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $1.35M | $684.42K | $200.00K | $150.00K | $347.50K | $978.00K | $885.50K | $952.00K | $1.49M | $3.24M | $3.39M | $2.41M | $3.69M | $1.84M | $12.50M | $2.73M | $1.11M | $1.02M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $1.35M | $456.28K | $200.00K | $150.00K | $347.50K | $978.00K | $885.50K | $952.00K | $1.49M | $3.24M | $3.39M | $2.41M | $3.69M | $1.84M | $12.50M | $2.73M | $738.44K | $682.92K |
| # Analysts | 9 | 13 | 17 | 9 | 8 | 8 | 10 | 14 | 16 | 9 | 9 | 2 | 1 | 19 | 12 | 16 | 18 | 9 | 9 | 11 | 12 | 16 | 10 | 10 | 5 | 5 | 5 | 5 | 12 | 17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.67% | 0.10% | 0.15% | 0.68% | 0.44% | 0.38% | 0.08% | 0.73% | 0.70% | 1.41% | 2.33% | 0.69% | 1.18% | 1.00% |
Corbus Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 16 analysts is $150.00K, with a low forecast of $150.00K, and a high forecast of $150.00K. CRBP's average Quarter revenue forecast represents a -164.14% decrease compared to the company's last Quarter revenue of $-233.88K (Dec 21).
Corbus Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 13 | 17 | 9 | 8 | 8 | 10 | 14 | 16 | 9 | 9 | 2 | 1 | 19 | 12 | 16 | 18 | 9 | 9 | 11 | 12 | 16 | 10 | 10 | 5 | 5 | 5 | 5 | 12 | 17 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-9.96M | $-7.67M | - | $-7.88M | $-12.09M | $-1.76M | $-16.72M | $-15.64M | $-8.18M | $-34.10M | $-37.64M | $-29.20M | $-26.18M | $-20.51M | $2.45M | $-25.99M | $-14.47M | $-11.94M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-269.96K | $-2.69M | $-40.00K | $-7.88M | $-69.50K | $-2.88M | $-12.54M | $-16.68M | $-298.08K | $-647.44K | $-25.10M | $-27.01M | $-737.08K | $-23.75M | $4.60M | $-11.65M | $-11.84M | $-11.94M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-269.96K | $-2.15M | $-40.00K | $-6.30M | $-69.50K | $-2.30M | $-10.03M | $-13.35M | $-298.08K | $-647.44K | $-20.08M | $-21.61M | $-737.08K | $-19.00M | $5.52M | $-9.32M | $-9.47M | $-9.56M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-269.96K | $-3.23M | $-40.00K | $-9.46M | $-69.50K | $-3.45M | $-15.05M | $-20.02M | $-298.08K | $-647.44K | $-30.12M | $-32.41M | $-737.08K | $-28.49M | $3.68M | $-13.98M | $-14.21M | $-14.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 36.88% | 2.85% | - | 1.00% | 173.98% | 0.61% | 1.33% | 0.94% | 27.45% | 52.66% | 1.50% | 1.08% | 35.51% | 0.86% | 0.53% | 2.23% | 1.22% | 1.00% |
5 analysts predict CRBP's average Quarter EBITDA for Sep 19 to be $-23.75M, with a high of $-19.00M and a low of $-28.49M. This is -1068.36% lower than Corbus Pharmaceuticals's previous annual EBITDA (Jun 19) of $2.45M.
Corbus Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 13 | 17 | 9 | 8 | 8 | 10 | 14 | 16 | 9 | 9 | 2 | 1 | 19 | 12 | 16 | 18 | 9 | 9 | 11 | 12 | 16 | 10 | 10 | 5 | 5 | 5 | 5 | 12 | 17 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-8.02M | $-8.98M | - | $-11.08M | $-12.35M | $-2.18M | $-17.14M | $-16.07M | $-8.61M | $-34.90M | $-38.11M | $-29.66M | $-26.58M | $-20.79M | $2.15M | $-26.23M | $-14.60M | $-12.07M |
| Avg Forecast | $-14.32M | $-12.34M | $-10.58M | $-9.03M | $-16.91M | $-15.78M | $-14.76M | $-14.15M | $-10.39M | $-10.35M | $-13.13M | $-9.06M | $-9.53M | $-3.33M | $-14.96M | $-9.44M | $-14.93M | $-3.56M | $-12.85M | $-17.14M | $-33.44M | $-53.88M | $-25.40M | $-27.43M | $-47.51M | $-24.07M | $4.04M | $-11.76M | $-11.95M | $-12.07M |
| High Forecast | $-14.32M | $-12.34M | $-10.58M | $-9.03M | $-16.91M | $-15.78M | $-14.76M | $-14.15M | $-10.39M | $-8.15M | $-13.13M | $-9.06M | $-8.97M | $-2.66M | $-14.96M | $-7.55M | $-14.93M | $-2.85M | $-10.28M | $-13.71M | $-33.44M | $-53.88M | $-20.32M | $-21.95M | $-47.51M | $-19.26M | $4.84M | $-9.41M | $-9.56M | $-9.66M |
| Low Forecast | $-14.32M | $-12.34M | $-10.58M | $-9.03M | $-16.91M | $-15.78M | $-14.76M | $-14.15M | $-10.39M | $-11.92M | $-13.13M | $-9.06M | $-10.10M | $-4.00M | $-14.96M | $-11.32M | $-14.93M | $-4.27M | $-15.42M | $-20.56M | $-33.44M | $-53.88M | $-30.48M | $-32.92M | $-47.51M | $-28.89M | $3.23M | $-14.11M | $-14.34M | $-14.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 2.70% | - | 1.17% | 0.83% | 0.61% | 1.33% | 0.94% | 0.26% | 0.65% | 1.50% | 1.08% | 0.56% | 0.86% | 0.53% | 2.23% | 1.22% | 1.00% |
Corbus Pharmaceuticals's average Quarter net income forecast for Sep 19 is $-24.07M, with a range of $-28.89M to $-19.26M. CRBP's average Quarter net income forecast represents a -1218.32% decrease compared to the company's last Quarter net income of $2.15M (Jun 19).
Corbus Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 13 | 17 | 9 | 8 | 8 | 10 | 14 | 16 | 9 | 9 | 2 | 1 | 19 | 12 | 16 | 18 | 9 | 9 | 11 | 12 | 16 | 10 | 10 | 5 | 5 | 5 | 5 | 12 | 17 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $2.98M | $4.07M | - | $5.23M | $4.23M | $5.28M | $5.57M | $5.34M | $5.36M | $7.68M | $7.74M | $7.70M | $6.28M | $5.53M | $5.21M | $6.62M | $3.18M | $2.99M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $8.92M | $3.77M | $1.32M | $991.61K | $2.30M | $6.47M | $5.85M | $6.29M | $9.85M | $21.40M | $22.42M | $15.94M | $24.36M | $12.15M | $9.76M | $18.06M | $6.10M | $5.64M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $8.92M | $4.52M | $1.32M | $991.61K | $2.30M | $6.47M | $5.85M | $6.29M | $9.85M | $21.40M | $22.42M | $15.94M | $24.36M | $12.15M | $11.72M | $18.06M | $7.32M | $6.77M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $8.92M | $3.02M | $1.32M | $991.61K | $2.30M | $6.47M | $5.85M | $6.29M | $9.85M | $21.40M | $22.42M | $15.94M | $24.36M | $12.15M | $7.81M | $18.06M | $4.88M | $4.51M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.33% | 1.08% | - | 5.28% | 1.84% | 0.82% | 0.95% | 0.85% | 0.54% | 0.36% | 0.35% | 0.48% | 0.26% | 0.46% | 0.53% | 0.37% | 0.52% | 0.53% |
Corbus Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CRBP last annual SG&A of $2.98M (Dec 23).
Corbus Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 13 | 17 | 9 | 8 | 8 | 10 | 14 | 16 | 9 | 9 | 2 | 1 | 19 | 12 | 16 | 18 | 9 | 9 | 11 | 12 | 16 | 10 | 10 | 5 | 5 | 5 | 5 | 12 | 17 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.81 | $-2.15 | - | $-2.66 | $-2.96 | $-0.52 | $-4.42 | $-4.14 | $-2.96 | $-12.79 | $-15.47 | $-12.84 | $-12.33 | $-9.65 | $0.94 | $-12.76 | $-7.66 | $-6.33 |
| Avg Forecast | $-1.30 | $-1.12 | $-0.96 | $-0.82 | $-1.53 | $-1.43 | $-1.33 | $-1.28 | $-0.94 | $-0.94 | $-1.19 | $-1.09 | $-2.15 | $-1.65 | $-1.80 | $-2.55 | $-3.38 | $-3.45 | $-3.54 | $-4.50 | $-7.56 | $-12.18 | $-11.25 | $-12.05 | $-10.74 | $-11.46 | $-4.95 | $-8.40 | $-0.18 | $-0.21 |
| High Forecast | $-1.30 | $-1.12 | $-0.96 | $-0.82 | $-1.53 | $-1.43 | $-1.33 | $-1.28 | $-0.94 | $-0.74 | $-1.19 | $-1.09 | $-2.03 | $-1.65 | $-1.80 | $-2.55 | $-3.38 | $-3.45 | $-3.54 | $-4.50 | $-7.56 | $-12.18 | $-11.25 | $-12.05 | $-10.74 | $-11.46 | $-4.95 | $-8.40 | $-0.14 | $-0.17 |
| Low Forecast | $-1.30 | $-1.12 | $-0.96 | $-0.82 | $-1.53 | $-1.43 | $-1.33 | $-1.28 | $-0.94 | $-1.08 | $-1.19 | $-1.09 | $-2.28 | $-1.65 | $-1.80 | $-2.55 | $-3.38 | $-3.45 | $-3.54 | $-4.50 | $-7.56 | $-12.18 | $-11.25 | $-12.05 | $-10.74 | $-11.46 | $-4.95 | $-8.40 | $-0.22 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 1.30% | - | 1.04% | 0.88% | 0.15% | 1.25% | 0.92% | 0.39% | 1.05% | 1.38% | 1.07% | 1.15% | 0.84% | -0.19% | 1.52% | 42.53% | 30.17% |
According to 5 Wall Street analysts, Corbus Pharmaceuticals's projected average Quarter EPS for Sep 19 is $-11.46, with a low estimate of $-11.46 and a high estimate of $-11.46. This represents a -1315.78% decrease compared to CRBP previous annual EPS of $0.94 (Jun 19).
Corbus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| KOD | Kodiak Sciences | $2.71 | $32.80 | 1110.33% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| TRVI | Trevi Therapeutics | $3.37 | $12.00 | 256.08% | Buy |
| BCAB | BioAtla | $1.81 | $5.00 | 176.24% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| AFMD | Affimed | $4.00 | $7.50 | 87.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
| CRBP | Corbus Pharmaceuticals | $55.81 | $74.00 | 32.59% | Buy |
| GLMD | Galmed Pharmaceuticals | $4.11 | $5.00 | 21.65% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| ADVM | Adverum Bio | $7.23 | $7.00 | -3.18% | Buy |
CRBP Forecast FAQ
Is Corbus Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Corbus Pharmaceuticals (CRBP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of CRBP's total ratings.
What is CRBP's price target?
Corbus Pharmaceuticals (CRBP) average price target is $74 with a range of $46 to $88, implying a 32.59% from its last price of $55.81. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Corbus Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for CRBP stock, the company can go up by 32.59% (from the last price of $55.81 to the average price target of $74), up by 57.68% based on the highest stock price target, and down by -17.58% based on the lowest stock price target.
Can Corbus Pharmaceuticals stock reach $80?
CRBP's highest twelve months analyst stock price target of $88 supports the claim that Corbus Pharmaceuticals can reach $80 in the near future.
What is Corbus Pharmaceuticals's current price target trend?
1 Wall Street analyst forecast a $74 price target for Corbus Pharmaceuticals (CRBP) this month, up 32.59% from its last price of $55.81. Compared to the last 3 and 12 months, the average price target increased by 44.54% and increased by 34.90%, respectively.
What are Corbus Pharmaceuticals's analysts' financial forecasts?
Corbus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-61.594M (high $-61.594M, low $-61.594M), average SG&A $0 (high $0, low $0), and average EPS is $-5.573 (high $-5.573, low $-5.573). CRBP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-46.27M (high $-46.27M, low $-46.27M), average SG&A $0 (high $0, low $0), and average EPS is $-4.186 (high $-4.186, low $-4.186).
Did the CRBP's actual financial results beat the analysts' financial forecasts?
Based on Corbus Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $881.7K, which missed the average analysts forecast of $3.16M by -72.12%. Apple's EBITDA was $-56.268M, beating the average prediction of $-32.167M by 74.93%. The company's net income was $-35.204M, missing the average estimation of $-48.481M by -27.39%. Apple's SG&A was $20.43M, missing the average forecast of $20.91M by -2.32%. Lastly, the company's EPS was $-8.59, missing the average prediction of $-14.865 by -42.21%. In terms of the last quarterly report (Dec 2021), Corbus Pharmaceuticals's revenue was $-234K, missing the average analysts' forecast of $347.5K by -167.30%. The company's EBITDA was $-12.091M, beating the average prediction of $-69.499K by 17297.69%. Corbus Pharmaceuticals's net income was $-12.354M, missing the average estimation of $-14.93M by -17.26%. The company's SG&A was $4.23M, beating the average forecast of $2.3M by 84.34%. Lastly, the company's EPS was $-2.96, missing the average prediction of $-3.375 by -12.30%